Insider buying · SEC Form 4

Insider Buying — Jul 17, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

2insider buys
$1.89Mbought in total
2companies
0by CEOs, CFOs and other chiefs
CRDFlargest: $1.00M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
CRDFCardiff Oncology Inc.Gary W. PaceDirector$1.00M687,285$1.46AddedJul 16, 2026
Form 4 ↗
Part of $10.05M registered direct offering at $1.455/share; also acquired 687,285 warrants at $1.33 strike. Post-buy holding 2,043,661 shares. Current price $0.875 (−39.9% from buy price). CRDF developing onvansertib (PLK1 inhibitor) for RAS-mutated CRC Phase 2.
FULCFulcrum Therapeutics Inc.Kevin Tang / Tang Capital Partners, L.P.10% Owner$888K249,946$3.55AddedJul 16, 2026
Form 4 ↗
Open-market accumulation across July 13–15 at weighted avg ~$3.55/share. Tang Capital group total stake now 6,913,329 shares (~8.2%). Current price $3.50 (−1.4% from avg buy). FULC developing losmapimod for FSHD.

AIThe day in insider buying

SEC Form 4 Insider Scan — July 17, 2026

Scanned the last 24 hours of EDGAR Form 4 filings. 2 qualifying buys (≥ $250K, transaction type P) totalling $1.9M.

Headline filings

  • CRDF — Gary W. Pace (Director) bought 687,285 shares ≈ $1.0M at $1.455 avg; now $0.87 (−39.9% since buy). Part of Cardiff Oncology's $10.05M registered direct offering announced July 15, 2026; also acquired 687,285 warrants at $1.33 exercise price. Post-buy holding: 2,043,661 shares. (filing)
  • FULC — Kevin Tang / Tang Capital Partners (10% Owner) bought 249,946 shares ≈ $887K at ~$3.55 weighted avg across July 13–15; now $3.50 (−1.4% since buy). Tang Capital group total stake now 6,913,329 shares (~8.2%). Steady accumulation play. (filing)

Notes

Both qualifying buys are in clinical-stage biotechs. CRDF (Cardiff Oncology) is advancing onvansertib, a PLK1 inhibitor, in Phase 2 trials for RAS-mutated colorectal cancer; the director's purchase came alongside a broader fundraise. FULC (Fulcrum Therapeutics) is focused on epigenetic therapies including losmapimod for facioscapulohumeral muscular dystrophy; Tang Capital has been methodically building its stake. The day's buy volume was light overall — most Form 4s filed July 16–17 were small ESPP/plan-driven transactions or sub-$250K purchases by officers at larger companies (FIS director: $57K; ANIX director: $9K). No cluster buys or large-cap executive purchases in this window.

Most-bought stocks, last 30 days

  • AVO $74.5M · 14 buys, 4 insidersMission Produce, Inc.
  • PBLS $10.0M · 1 buyParabilis Medicines, Inc.
  • PSEC $9.35M · 3 buys, 2 insidersProspect Capital Corp
  • NTSK $7.53M · 2 buys, 2 insidersNetskope Inc.
  • HDSN $6.10M · 2 buys, 2 insidersHudson Technologies, Inc.
  • STEP $5.02M · 1 buyStepStone Group Inc.
  • NVCT $4.66M · 8 buys, 2 insidersNuvectis Pharma, Inc.
  • ARTV $4.60M · 1 buyArtiva Biotherapeutics Inc.
  • ENR $3.71M · 3 buys, 2 insidersEnergizer Holdings, Inc.
  • COE $3.64M · 2 buys51Talk Online Education Group (China Online Education Group)
  • GLOO $3.50M · 1 buyGloo Holdings, Inc.
  • FISV $2.74M · 6 buys, 4 insidersFiserv Inc.
  • WBX $2.25M · 2 buys, 2 insidersWallbox N.V.
  • GGAL $2.09M · 1 buyGrupo Financiero Galicia S.A.
  • AMR $2.01M · 1 buyAlpha Metallurgical Resources Inc.
  • NXST $1.99M · 1 buyNexstar Media Group, Inc.
  • ADBE $1.95M · 1 buyAdobe Inc
  • RH $1.83M · 1 buyRH
  • JCTC $1.61M · 2 buys, 2 insidersJewett-Cameron Trading Co. Ltd.
  • AMS $1.34M · 1 buyAmerican Shared Hospital Services

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.